Back to news

European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Globe Newswire•16/11/2026•13:00 ET
0

Key Highlights

  • ➤European Commission approves RASONQUE for previously treated metastatic pancreatic adenocarcinoma
  • ➤EU approval covers patients with or without identified RAS tumor mutations
  • ➤Marketing authorization spans all EU member states plus Iceland, Norway, and Liechtenstein
  • ➤Patient access timing depends on country-specific pricing, assessment, and reimbursement processes
  • ➤RASONQUE Phase 3 trial met primary and key secondary endpoints in RAS G12 and overall populations

Expert Statements

Thomas Seufferlein, Medical director, Clinic for Internal Medicine I, Ulm University Hospital

“For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches.”

Thomas Seufferlein, Medical director, Clinic for Internal Medicine I, Ulm University Hospital

“The European Commission’s approval of daraxonrasib represents an important advance for patients with this aggressive and difficult-to-treat disease.”

Thomas Seufferlein, Medical director, Clinic for Internal Medicine I, Ulm University Hospital

“The unprecedented survival benefit demonstrated in the RASolute 302 clinical trial underscores the potential of daraxonrasib to establish a new standard of care for eligible patients with metastatic pancreatic cancer across the European Union.”

Mark A. Goldsmith, Chief executive officer and chairman of Revolution Medicines

“Today’s European Commission approval of RASONQUE represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families.”

Mark A. Goldsmith, Chief executive officer and chairman of Revolution Medicines

“With RASONQUE now approved, we are actively working with healthcare systems and stakeholders across the region to support timely access for eligible patients.”

Mark A. Goldsmith, Chief executive officer and chairman of Revolution Medicines

“We also continue to engage with regulatory authorities around the world with the goal of expanding and accelerating the reach of RASONQUE to patients who may benefit from it.”

* RASONQUE once-daily oral tablets indicated as a monotherapy for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy * Approval includes patients with or without an identified RAS tumor mutation * Revolution Medicines is working to enable patient access in European Union, with timing dependent on country-specific pricing and reimbursement processes REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.(1) RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in